A symposium on microbiology in the pharmaceutical sector was the opportunity for the European Directorate for the Quality of Medicines & HealthCare (EDQM) to gather feedback from users of the European Pharmacopoeia on alternative testing methods for microbiological control and sterilisation processes. The event, which took place in Strasbourg on 10−11 October 2017, was attended by a wide range of experts in the pharmaceutical and microbiological fields who reviewed the latest trends and innovations in the field of microbiology, in addition to pharmacopoeial approaches and related regulatory requirements.
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP
- Pricing and reimbursement of medicines in Canada
- Medicines pricing conditions in Italy and Brazil: comparison of regulations
- Relevance of NTI to the treatment of epilepsy
- What is the meaning of a narrow therapeutic index?
- EC approves bevacizumab biosimilar Vegzelma
- FDA accepts application for high concentration adalimumab biosimilar
- EC approves ranibizumab biosimilar Ranivisio
- Applications for natalizumab biosimilars accepted by FDA and EMA
- Recommendations to address challenges to biosimilars in Latin America
- Regulatory landscape for biosimilars in Latin America
- Totality of evidence for biosimilar pegfilgrastim Ziextenzo
- What does the designation of interchangeability for biosimilars in the US mean?
- MORE EDITORIAL SECTIONS